NasdaqGS:NVAXBiotechs
Should US FDA Approval of Updated Nuvaxovid Spur Action From Novavax (NVAX) Investors?
On August 27, 2025, Novavax announced that the U.S. FDA approved the Nuvaxovid 2025-2026 formula for COVID-19 prevention in adults 65 and older, as well as individuals aged 12-64 with underlying conditions that increase their risk of severe illness.
This approval underscores the vaccine’s demonstrated broad immunity against a range of circulating JN.1 lineage COVID-19 strains, expanding Novavax’s reach in key high-risk populations.
We'll assess how this regulatory milestone for Nuvaxovid's...